BACKGROUND:T-cell interferon-γ release assays (IGRAs) are used in the diagnosis of Mycobacterium tuberculosis infection and could be useful biomarkers of response to treatment of latent TB infection for clinical trials, infection control units, and TB programs. METHODS: This investigation was a prospective, controlled substudy of IGRA responses in 82 healthy South African adults with HIV seronegative and positive tuberculin skin test results randomly assigned to treatment with 6 months of daily isoniazid preventive therapy (IPT) or observation before Bacillus Calmette-Guérin revaccination in a clinical trial. QuantiFERON-TB Gold In-Tube (QFT-GIT) assay was used to measure interferon-γ (IFN-γ) response to mycobacterial antigens at baseline and after IPT or observation. RESULTS:IFN-γ levels declined between baseline and the end of IPT (signed rank test P≤.0001) and between baseline and a similar period of observation without IPT (signed rank test P=.03). The rate of decrease in IFN-γ responses over time did not differ between the groups (Mann-Whitney-Wilcoxon test P=.31). QFT-GIT test results in two subjects (5%) in the IPT group and two subjects (5%) in the observation group reverted from positive to negative during follow-up. No significant difference was found between the groups with respect to baseline positivity or the proportion of patients whose tests reverted to negative. CONCLUSIONS:IPT had no effect on changes in QFT-GIT readouts during short-term follow-up of adults with positive tuberculin skin tests in a high TB incidence setting. QFT-GIT is unlikely to be a useful biomarker of response to treatment of latent TB infection. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT01119521; URL: www.clinicaltrials.gov.
RCT Entities:
BACKGROUND: T-cell interferon-γ release assays (IGRAs) are used in the diagnosis of Mycobacterium tuberculosis infection and could be useful biomarkers of response to treatment of latent TB infection for clinical trials, infection control units, and TB programs. METHODS: This investigation was a prospective, controlled substudy of IGRA responses in 82 healthy South African adults with HIV seronegative and positive tuberculin skin test results randomly assigned to treatment with 6 months of daily isoniazid preventive therapy (IPT) or observation before Bacillus Calmette-Guérin revaccination in a clinical trial. QuantiFERON-TB Gold In-Tube (QFT-GIT) assay was used to measure interferon-γ (IFN-γ) response to mycobacterial antigens at baseline and after IPT or observation. RESULTS: IFN-γ levels declined between baseline and the end of IPT (signed rank test P≤.0001) and between baseline and a similar period of observation without IPT (signed rank test P=.03). The rate of decrease in IFN-γ responses over time did not differ between the groups (Mann-Whitney-Wilcoxon test P=.31). QFT-GIT test results in two subjects (5%) in the IPT group and two subjects (5%) in the observation group reverted from positive to negative during follow-up. No significant difference was found between the groups with respect to baseline positivity or the proportion of patients whose tests reverted to negative. CONCLUSIONS:IPT had no effect on changes in QFT-GIT readouts during short-term follow-up of adults with positive tuberculin skin tests in a high TB incidence setting. QFT-GIT is unlikely to be a useful biomarker of response to treatment of latent TB infection. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT01119521; URL: www.clinicaltrials.gov.
Authors: Adam J Gehring; Roxana E Rojas; David H Canaday; David L Lakey; Clifford V Harding; W Henry Boom Journal: Infect Immun Date: 2003-08 Impact factor: 3.441
Authors: K Dheda; A Pooran; M Pai; R F Miller; K Lesley; H L Booth; G M Scott; A N Akbar; A Zumla; G A Rook Journal: J Infect Date: 2007-04-19 Impact factor: 6.072
Authors: S Xu; A Cooper; S Sturgill-Koszycki; T van Heyningen; D Chatterjee; I Orme; P Allen; D G Russell Journal: J Immunol Date: 1994-09-15 Impact factor: 5.422
Authors: Scott A Fulton; Scott M Reba; Rish K Pai; Meghan Pennini; Martha Torres; Clifford V Harding; W Henry Boom Journal: Infect Immun Date: 2004-04 Impact factor: 3.441
Authors: Patricio Escalante; Tobias Peikert; Virginia P Van Keulen; Courtney L Erskine; Cathy L Bornhorst; Boleyn R Andrist; Kevin McCoy; Larry R Pease; Roshini S Abraham; Keith L Knutson; Hirohito Kita; Adam G Schrum; Andrew H Limper Journal: Am J Respir Crit Care Med Date: 2015-09-01 Impact factor: 21.405
Authors: Mark Hatherill; Thomas J Scriba; Sara Suliman; Hennie Geldenhuys; John L Johnson; Jane E Hughes; Erica Smit; Melissa Murphy; Asma Toefy; Lesedi Lerumo; Christiaan Hopley; Bernadette Pienaar; Phalkun Chheng; Elisa Nemes; Daniel F Hoft; Willem A Hanekom; W Henry Boom Journal: J Immunol Date: 2016-07-13 Impact factor: 5.422
Authors: Julie G Burel; Akul Singhania; Paige Dubelko; Julius Muller; Rachel Tanner; Eneida Parizotto; Martin Dedicoat; Thomas E Fletcher; James Dunbar; Adam F Cunningham; Cecilia S Lindestam Arlehamn; Donald G Catanzaro; Antonino Catanzaro; Timothy Rodwell; Helen McShane; Matthew K O'Shea; Bjoern Peters Journal: Tuberculosis (Edinb) Date: 2021-09-14 Impact factor: 3.131
Authors: Mark Hatherill; Hendrik Geldenhuys; Bernadette Pienaar; Sara Suliman; Phalkun Chheng; Sara M Debanne; Daniel F Hoft; W Henry Boom; Willem A Hanekom; John L Johnson Journal: Vaccine Date: 2014-05-09 Impact factor: 3.641